141 related articles for article (PubMed ID: 30092273)
1. The role of nutraceuticals in the treatment of primary dyslipidemia.
Sanidas E; Grassos C
Hellenic J Cardiol; 2020; 61(1):60-62. PubMed ID: 30092273
[No Abstract] [Full Text] [Related]
2. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia.
Fonseca HA; Izar MC; Bianco HT; Fonseca FA
J Atheroscler Thromb; 2010 Aug; 17(8):888. PubMed ID: 20702973
[No Abstract] [Full Text] [Related]
4. Ezetimibe: rescued by randomization (clinical and mendelian).
McPherson R; Hegele RA
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):e13-5. PubMed ID: 25550209
[No Abstract] [Full Text] [Related]
5. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
6. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
Nozue T; Michishita I; Mizuguchi I
J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.
Marazzi G; Pelliccia F; Campolongo G; Quattrino S; Cacciotti L; Volterrani M; Gaudio C; Rosano G
Am J Cardiol; 2015 Dec; 116(12):1798-801. PubMed ID: 26611120
[TBL] [Abstract][Full Text] [Related]
8. [Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Martínez-Abundis E; Barrera-Durán C; González-Ortiz M; Hernández-Salazar E
Gac Med Mex; 2016 Oct; 152(Suppl 2):88-95. PubMed ID: 27792720
[TBL] [Abstract][Full Text] [Related]
9. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.
Strilchuk L; Tocci G; Fogacci F; Cicero AFG
Expert Opin Pharmacother; 2020 Apr; 21(5):531-539. PubMed ID: 32036729
[No Abstract] [Full Text] [Related]
10. Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.
Scognamiglio M; Costa D; Sorriento A; Napoli C
Curr Pharm Des; 2019; 25(1):85-95. PubMed ID: 30706799
[TBL] [Abstract][Full Text] [Related]
11. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-Lowering Bioactive Foods and Nutraceuticals in Pediatrics: Clinical Evidence of Efficacy and Safety.
Fogacci F; ALGhasab NS; Di Micoli V; Giovannini M; Cicero AFG
Nutrients; 2024 May; 16(10):. PubMed ID: 38794764
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy.
Khan SU; Khan MU; Riaz H; Raggi P; Valavoor S; Khan MZ; Kołodziejczak M; Khan MS; Krupica T; Alkhouli M; Navarese EP
Am J Cardiol; 2020 Mar; 125(5):727-734. PubMed ID: 31898964
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.
Miura S; Saku K
J Cardiol; 2008 Aug; 52(1):1-6. PubMed ID: 18639771
[TBL] [Abstract][Full Text] [Related]
16. [A decade of progress in the management of dyslipidemia].
Wallemacq C; Paquot N
Rev Med Liege; 2020 May; 75(5-6):386-391. PubMed ID: 32496685
[TBL] [Abstract][Full Text] [Related]
17. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
18. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Folse HJ; Goswami D; Rengarajan B; Budoff M; Kahn R
Atherosclerosis; 2014 Sep; 236(1):154-61. PubMed ID: 25050538
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
